How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?
Moderna (NASDAQ: MRNA) currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, one of which will advance into late-stage clinical studies this year
Pfizer (NYSE: PFE) is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.
Pfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.
Source Fool.com
